Business context and reporting period
Baird Medical Investment Holdings Limited, a Cayman Islands company that files annual reports on Form 20-F, furnished this Form 6-K for September 2026. The filing reports a September 24, 2026 securities purchase agreement; it does not provide quarterly or year-to-date operating results.
Financing terms and key financial implications
- The Company agreed to issue an institutional investor a senior convertible promissory note with stated principal of US$4,347,826, an 8% original issue discount, and a 12-month term. The filing does not state the net cash proceeds.
- The note has no accruing interest unless an event of default occurs. During a default, interest is 15% annually, or the maximum permitted by law if lower, compounded monthly.
- An additional 2% discount on the subscription amount, stated as US$86,956, was settled with 110,070 ordinary shares. The share calculation used US$0.79 per share.
- The purchaser is obligated to provide an additional US$3.68 million within 180 days of the first closing if specified conditions are met, including a preceding-day closing price above US$1.00, effective resale registration, less than US$300,000 of note principal outstanding, and satisfaction of other conditions. A further US$6 million may be lent in two closings within 360 days, subject to mutual consent.
- The note ranks senior to the Company’s other existing indebtedness and equity. The Company’s subsidiaries, other than an excluded subsidiary, provided a guarantee. The Company pledged its equity in Baird Med LLC and certain qualifying U.S. subsidiaries; the Company and Baird Med LLC also granted a security interest in substantially all their U.S.-located assets, subject to exclusions.
Conversion, dilution, and material changes
- The investor may convert principal and any accrued interest into ordinary shares. The conversion price is the lower of US$0.9842 or 92% of the lowest daily VWAP during the preceding seven trading days; the variable rate becomes 85% upon an event of default. A floor price, defined as 20% of the Nasdaq minimum price, applies, with specified alternatives if the calculated price is below the floor.
- Conversion is restricted if it would cause the investor and attribution parties to beneficially own more than 9.99% of the outstanding ordinary shares. The filing does not quantify potential total dilution.
- Compared with the prior comparable period, no operating or financial comparison is provided. The material change disclosed is the new secured, senior convertible financing and related share issuance.
Outlook, risks, and unusual items
The filing gives no operating guidance, outlook, revenue, profit, cash-flow, margin, debt-balance, or liquidity metrics. Financing-related risks include potential dilution from conversion, a discounted variable conversion price, default interest, and the grant of guarantees and security over specified subsidiary equity and U.S. assets. The additional US$3.68 million is conditional, and the potential US$6 million requires mutual consent; neither should be treated as assured funding.
Key facts for investors to verify
- Actual closing date, net proceeds, use of proceeds, and current principal outstanding under the note.
- Whether conditions for the additional US$3.68 million are met and whether the parties agree to the potential US$6 million financing.
- Applicable conversion price and floor price, registration-statement availability, and resulting potential share dilution.
- Scope and practical effect of the subsidiary guarantee, pledged interests, collateral, and excluded assets.
- Any defaults, conversions, repayments, or subsequent financing developments not covered in this filing.